CYSTIC TRANSFORMATION OF THE PANCREAS DUE TO VON HIPPEL–LINDAU SYNDROME
https://doi.org/10.16931/1995-5464.20172104-108
Abstract
It is presented clinical observation of the patient with cystic pancreatic transformation and von Hippel-Lindau syndrome. The possibilities of molecular-genetic testing for this disease are shown. The observation illustrates the need for detailed clinical examination and molecular genetic testing for cystic pancreatic transformation in young patients without chronic pancreatitis.
About the Authors
A. A. Shikeeva
Medical and Rehabilitation Center, Health Ministry of the Russian Federation;
Research Centre for Medical Genetics;
Russian Medical Academy of Postgraduate Education, Health Ministry of the Russian Federation
Russian Federation
Shikeeva Amulang Alekseevna – Cand. of Med. Sci., Genetic Counselor at the Medical and Rehabilitation Center of Health Ministry of the Russian Federation; Senior Researcher at the Laboratory of Epigenetics, Research Centre for Medical Genetics; Senior Researcher, Department of Fundamental Research, Russian Medical Academy of Postgraduate Education of Health Ministry of the Russian Federation
Russian Federation
Shikeeva Amulang Alekseevna – Cand. of Med. Sci., Genetic Counselor at the Medical and Rehabilitation Center of Health Ministry of the Russian Federation; Senior Researcher at the Laboratory of Epigenetics, Research Centre for Medical Genetics; Senior Researcher, Department of Fundamental Research, Russian Medical Academy of Postgraduate Education of Health Ministry of the Russian Federation
V. К. Lyadov
Medical and Rehabilitation Center, Health Ministry of the Russian Federation;
Russian Medical Academy of Postgraduate Education, Health Ministry of the Russian Federation
Russian Federation
Russian Federation
Lyadov Vladimir Konstantinovich – Cand. of Med. Sci., Head of the Department of Surgical Oncology, Medical and Rehabilitation Center of Health Ministry of the Russian Federation; Assistant at the Chair of Oncology of Russian Medical Academy of Postgraduate Education of Health Ministry of the Russian Federation
For correspondence: Lyadov Vladimir Konstantinovich – 3, Ivankovskoye schosse, Moscow, 125367, Federal State Medical and Rehabilitation Center under the Ministry of Health, Russian Federation. Phone: +7-916-195-68-27. E-mail: vlyadov@gmail.com
T. V. Kekeeva
Medical and Rehabilitation Center, Health Ministry of the Russian Federation;
Research Centre for Medical Genetics;
Russian Medical Academy of Postgraduate Education, Health Ministry of the Russian Federation
Russian Federation
Kekeeva Tat’yana Vladimirovna – Cand. of Med. Sci., Head of the Laboratory of Molecular Genetics, Medical and Rehabilitation Center of Health Ministry of the Russian Federation; Leading Researcher at the Laboratory of Epigenetics, Research Centre for Medical Genetics; Associate Professor at the Pathological Anatomy Department, Russian Medical Academy of Postgraduate Education of Health Ministry of the Russian Federation �рава России
Russian Federation
Kekeeva Tat’yana Vladimirovna – Cand. of Med. Sci., Head of the Laboratory of Molecular Genetics, Medical and Rehabilitation Center of Health Ministry of the Russian Federation; Leading Researcher at the Laboratory of Epigenetics, Research Centre for Medical Genetics; Associate Professor at the Pathological Anatomy Department, Russian Medical Academy of Postgraduate Education of Health Ministry of the Russian Federation �рава России
D. S. Mikhaylenko
Research Centre for Medical Genetics;
N.A. Lopatkin Research Institute of Urology and Interventional Radiology
Russian Federation
Mikhaylenko Dmitriy Sergeevich – Cand. of Med. Sci., Associate Professor, Leading Researcher, Department of Pathological Anatomy and Molecular Genetics, N.A. Lopatkin Research Institute of Urology and Interventional Radiology, Branch of the National Medical Research Radiological Centre of Health Ministry of the Russian Federation; Laboratory Geneticist, Research Centre for Medical Genetics
Russian Federation
Mikhaylenko Dmitriy Sergeevich – Cand. of Med. Sci., Associate Professor, Leading Researcher, Department of Pathological Anatomy and Molecular Genetics, N.A. Lopatkin Research Institute of Urology and Interventional Radiology, Branch of the National Medical Research Radiological Centre of Health Ministry of the Russian Federation; Laboratory Geneticist, Research Centre for Medical Genetics
References
1. Feletti A., Anglani M., Scarpa B., Schiavi F., Boaretto F., Zovato S., Taschin E., Gardi M., Zanoletti E., Piermarocchi S., Murgia A., Pavesi G., Opocher G. Von Hippel-Lindau disease: an evaluation of natural history and functional disability. NeuroOncol. 2016; 18 (7): 1011-1020. DOI: 10.1093/neuonc/nov313.
2. Chen F., Slife L., Kishida T., Mulvihill J., Tisherman S.E., Zbar B. Genotype-phenotype correlation in von Hippel-Lindau disease identification of a mutation associated with VHL type A. J. Med. Genet. 1996; 33 (8): 716-717.
3. Frantzen C., Klasson T.D., Links T.P., Giles R.H. Von Hippel-Lindau Syndrome. In: Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Fong C.T., Mefford H.C., Smith R.J.H., Stephens K., еds. Gene Reviews, 2000. Seattle (WA): University of Washington, Seattle; 1993-2016. ISSN: 2372-0697.
4. Ершова Е.В., Юкина М.Ю., Трошина Е.А., Бельцевич Д.Г., Мустафаева Э.З. Синдром фон Хиппеля-Линдау. Ожирение и метаболизм. 2011; 2: 65-68.
5. Алексеев Б.Я., Калпинский А.С., Исаев А.Р., Москвина Л.В., Нюшко К.М., Воробьев Н.В., Каприн А.Д. Органосохраняющее лечение больных с VHL-синдромом. Онкология. Журнал им. П.А. Герцена. 2014; 5: 57-60.
6. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., Stackhouse T., Kuzmin I., Modi W., Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993; 260 (5112): 1317-1320.
7. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2002; 2 (9): 673-682.
8. Pugh C.W., Ratcliffe P.J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol. 2003; 13 (1): 83-89.
9. Vaganovs P., Bokums K., Miklaševics E., Plonis J., Zarina L., Geldners I., Gardovskis J., Vjaters E. Von Hippel-Lindau syndrome: diagnosis and management of hemangioblastoma and pheochromocytoma. Case Rep. Urol. 2013; 2013: 624096. DOI: 10.1155/2013/624096.
10. Friedrich C.A. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum. Mol. Genet. 2001; 10 (7): 763-767.
11. Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., Oldfield E.H. Von Hippel-Lindau disease. Lancet. 2003; 361 (9374): 2059-2067.
12. MD Anderson Cancer Center URL: https://www.mdanderson.org/cancer-types/von-hippel-lindau-disease.html
13. Binderup M.L., Bisgaard M.L., Harbud V., Møller H.U., Gimsing S., Friis-Hansen L., Hansen Tv., Bagi P., Knigge U., Kosteljanetz M., Bøgeskov L., Thomsen C., Gerdes A.M., Ousager L.B., Sunde L.; Danish vHL Coordination Group. Von Hippel-Lindau disease (vHL). National clinical guidelinefor diagnosis and surveillance in Denmark. 3rd edition. Dan. Med. J. 2013; 60 (12): B4763.
14. VHL Alliance URL: https://vhl.org/
15. Pavesi G., Feletti A., Berlucchi S., Opocher G., Martella M., Murgia A., Scienza R. Neurosurgical treatment of von Hippel-Lindau-associated hemangioblastomas: benefits, risks and outcome. J. Neurosurg. Sci. 2008; 52 (2): 29-36.
16. Capitanio J.F., Mazza E., Motta M., Mortini P., Reni M. Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system. Crit. Rev. Oncol. Hematol. 2013; 86 (1): 69-84. DOI: 10.1016/j.critrevonc.2012.10.001.
17. Schmid S., Gillessen S., Binet I., Brändle M., Engeler D., Greiner J., Hader C., Heinimann K., Kloos P., Krek W., Krull I., Stoeckli S.J., Sulz M.C., van Leyen K., Weber J., Rothermundt C., Hundsberger T. Management of von Hippel-Lindau disease: an interdisciplinary review. Oncol. Res. Treat. 2014; 37 (12): 761-771. DOI: 10.1159/000369362.
18. Jonasch E., McCutcheon I.E., Waguespack S.G., Wen S., Davis D.W., Smith L.A., Tannir N.M., Gombos D.S., Fuller G.N., Matin S.F. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann. Oncol. 2011; 22 (12): 2661-2666. DOI: 10.1093/annonc/mdr011.
19. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., Zarbá J.J., Chen M., McCann L., Pandite L., Roychowdhury D.F., Hawkins R.E. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010; 28 (6): 1061-1068. DOI: 10.1200/JCO.2009.23.9764.
20. Motzer R.J., Hutson T.E., Cella D., Reeves J., Hawkins R., Guo J., Nathan P., Staehler M., deSouza P., Merchan J.R., Boleti E., Fife K., Jin J., Jones R., Uemura H., De Giorgi U., Harmenberg U., Wang J., Sternberg C.N., Deen K., McCann L., Hackshaw M.D., Crescenzo R., Pandite L.N., Choueiri T.K. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 2013; 369 (8): 722-731. DOI: 10.1056/NEJMoa1303989.
21. Jimenez C., Cabanillas M.E., Santarpia L., Jonasch E., Kyle K.L., Lano E.A., Matin S.F., Nunez R.F., Perrier N.D., Phan A., Rich T.A., Shah B., Williams M.D., Waguespack S.G. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease related tumors. J. Clin. Endocrinol. Metab. 2009; 94 (2): 386-391. DOI: 10.1210/jc.2008-1972.
22. Kim B.Y., Jonasch E., McCutcheon I.E. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report. Target Oncol. 2012; 7 (2): 145-149. DOI: 10.1007/s11523-012-0214-0.
23. Omar A.I. Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report. J. Med. Case Rep. 2012; 6: 238. DOI: 10.1186/1752-1947-6-238.
24. von Buelow M., Pape S., Hoerauf H. Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. Acta Ophthalmol. Scand. 2007; 85 (1): 114-116.
25. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O''Toole T., Lustgarten S., Moore L., Motzer R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356 (22): 2271-2281.
Review
For citations:
Shikeeva A.A., Lyadov V.К., Kekeeva T.V., Mikhaylenko D.S. CYSTIC TRANSFORMATION OF THE PANCREAS DUE TO VON HIPPEL–LINDAU SYNDROME. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2017;22(2):104-108. (In Russ.) https://doi.org/10.16931/1995-5464.20172104-108
Views:
1846
Email this article 